Multiple Myeloma, Refractory Clinical Trial
Official title:
Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer antigens. While CAR-NK therapy offers advantages over CAR-T therapy, such as reduced immune system reactions and lower production time and cost, challenges remain in terms of antitumor efficacy and the tumor microenvironment. Preclinical and early clinical studies have targeted various antigens, including BCMA, with CAR-NK cells in multiple myeloma. To further investigate the potential of BCMA-targeted CAR-NK cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (MTD) in patients who have not responded to standard therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06411301 -
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
|
Phase 1 | |
| Recruiting |
NCT05008536 -
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
|
Early Phase 1 | |
| Recruiting |
NCT06158412 -
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05121103 -
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 | |
| Recruiting |
NCT04657861 -
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
|
Early Phase 1 | |
| Terminated |
NCT05191472 -
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
|
Phase 2 | |
| Active, not recruiting |
NCT04688853 -
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
|
Phase 1 | |
| Not yet recruiting |
NCT05050305 -
Marizomib Central Nervous System (CNS)
|
Phase 2 | |
| Recruiting |
NCT05546723 -
LMY-920 for Treatment of Relapsed or Refractory Myeloma
|
Phase 1 | |
| Not yet recruiting |
NCT06225310 -
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
|
Phase 1 | |
| Not yet recruiting |
NCT06115135 -
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05673083 -
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
|
||
| Completed |
NCT02176213 -
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Enrolling by invitation |
NCT04861480 -
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT06012383 -
Alvocade® (Bortezomib) Safety and Effectiveness Study
|
||
| Not yet recruiting |
NCT05909826 -
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
|
Phase 2 | |
| Recruiting |
NCT04414475 -
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
|
Phase 2 | |
| Completed |
NCT04811898 -
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
|
Phase 1 | |
| Recruiting |
NCT05739188 -
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
|
Phase 1/Phase 2 |